ASTRAZENECA PHARMA | VENUS REMEDIES | ASTRAZENECA PHARMA/ VENUS REMEDIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 117.1 | -13.4 | - | View Chart |
P/BV | x | 35.8 | 0.9 | 3,990.0% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
VENUS REMEDIES Mar-18 |
ASTRAZENECA PHARMA/ VENUS REMEDIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 126 | 1,015.1% | |
Low | Rs | 883 | 61 | 1,444.5% | |
Sales per share (Unadj.) | Rs | 228.4 | 301.8 | 75.7% | |
Earnings per share (Unadj.) | Rs | 10.4 | -24.9 | -41.7% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 2.5 | 639.0% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Dividend yield (eoy) | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 98.8 | 293.3 | 33.7% | |
Shares outstanding (eoy) | m | 25.00 | 12.34 | 202.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 0.3 | 1,526.7% | |
Avg P/E ratio | x | 104.2 | -3.8 | -2,772.6% | |
P/CF ratio (eoy) | x | 66.4 | 36.7 | 180.8% | |
Price / Book Value ratio | x | 10.9 | 0.3 | 3,430.7% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 27,008 | 1,154 | 2,340.8% | |
No. of employees | `000 | 1.4 | 0.9 | 146.6% | |
Total wages/salary | Rs m | 1,535 | 393 | 390.6% | |
Avg. sales/employee | Rs Th | 4,210.9 | 4,026.1 | 104.6% | |
Avg. wages/employee | Rs Th | 1,132.2 | 425.0 | 266.4% | |
Avg. net profit/employee | Rs Th | 191.1 | -331.8 | -57.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 3,724 | 153.3% | |
Other income | Rs m | 123 | 23 | 544.4% | |
Total revenues | Rs m | 5,833 | 3,747 | 155.7% | |
Gross profit | Rs m | 463 | 395 | 117.2% | |
Depreciation | Rs m | 147 | 338 | 43.6% | |
Interest | Rs m | 0 | 354 | 0.0% | |
Profit before tax | Rs m | 438 | -275 | -159.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | 32 | 566.1% | |
Profit after tax | Rs m | 259 | -307 | -84.4% | |
Gross profit margin | % | 8.1 | 10.6 | 76.5% | |
Effective tax rate | % | 40.8 | -11.5 | -355.8% | |
Net profit margin | % | 4.5 | -8.2 | -55.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 2,638 | 121.7% | |
Current liabilities | Rs m | 2,070 | 2,305 | 89.8% | |
Net working cap to sales | % | 20.0 | 8.9 | 223.2% | |
Current ratio | x | 1.6 | 1.1 | 135.5% | |
Inventory Days | Days | 72 | 135 | 53.4% | |
Debtors Days | Days | 35 | 46 | 75.4% | |
Net fixed assets | Rs m | 790 | 4,871 | 16.2% | |
Share capital | Rs m | 50 | 123 | 40.5% | |
"Free" reserves | Rs m | 2,419 | 3,496 | 69.2% | |
Net worth | Rs m | 2,469 | 3,619 | 68.2% | |
Long term debt | Rs m | 0 | 1,374 | 0.0% | |
Total assets | Rs m | 4,605 | 7,509 | 61.3% | |
Interest coverage | x | NM | 0.2 | - | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.5 | 250.0% | |
Return on assets | % | 5.6 | 0.6 | 891.2% | |
Return on equity | % | 10.5 | -8.5 | -123.7% | |
Return on capital | % | 17.7 | 1.6 | 1,121.2% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 13.9 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 517 | 0.0% | |
Fx inflow | Rs m | 300 | 0 | - | |
Fx outflow | Rs m | 2,015 | 517 | 390.1% | |
Net fx | Rs m | -1,715 | -517 | 332.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 514 | 17.1% | |
From Investments | Rs m | -94 | -123 | 76.0% | |
From Financial Activity | Rs m | NA | -387 | 0.0% | |
Net Cashflow | Rs m | -6 | 4 | -135.7% |
Indian Promoters | % | 0.0 | 32.9 | - | |
Foreign collaborators | % | 75.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.3 | 0.2 | 166.7% | |
FIIs | % | 15.7 | 0.6 | 2,706.9% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 66.4 | 13.7% | |
Shareholders | 12,856 | 20,121 | 63.9% | ||
Pledged promoter(s) holding | % | 0.0 | 36.4 | - |
Compare ASTRAZENECA PHARMA With: CIPLA PFIZER ALEMBIC PHARMA SHASUN PHARMA SANOFI INDIA
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.
For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
What should you do if the market falls? In this video, I'll tell you what I will do.
A favourable demand supply scenario makes a strong case for real estate prices.
Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market
More